-
by
MedPAC Staff
| Jan 27, 2016
Evidence suggests that price growth for brand-name drugs is beginning to drive growth in average prices of all drugs covered under Part D.
Full post
-
by
MedPAC Staff
| Jan 19, 2016
Every year, the Commission provides a status report on the Medicare Advantage (MA) and Part D programs. These reports were presented at our December and January meetings. To monitor each program’s performance, we examine enrollment trends, and plan availability for the coming year, as well as a variety of other factors.
Full post
-
by
MedPAC Staff
| Sep 01, 2015
At the end of July, CMS announced that enrollee premiums for Medicare’s outpatient prescription drug benefit, known as Part D, will remain stable for 2016 at an average of $32.50 per month. It marks continued good news for Part D enrollees, whose average premiums have remained at about $30 to $32 per month for the past 7 years. However, other trends are more worrisome for the taxpayers supporting the Part D program.
Full post
-
by
MedPAC Staff
| Oct 22, 2014
At MedPAC’s October public meeting, the Commission discussed patterns of potentially inappropriate opioid use in Medicare’s prescription drug benefit, Part D. In 2011, 10 million beneficiaries, or about 32 percent of Part D enrollees filled at least one prescription for an opioid. The share of Part D enrollees who use opioids in varies considerably across states.
Full post
-
by
MedPAC Staff
| Oct 15, 2014
At MedPAC’s public meeting last week, the Commission discussed how Medicare shares financial risk with Part D prescription drug plans.
Full post